FilingReader Intelligence
Changchun High & New gets cancer drug trial approval
August 21, 2025 at 05:36 PM UTC•By FilingReader AI
Changchun High & New Technology Industry Group announced its subsidiary Changchun GeneScience Pharmaceuticals received acceptance from China's National Medical Products Administration for clinical trials of GenSci143.
The bispecific antibody-drug conjugate targets B7-H3 and PSMA for treating advanced solid tumors.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000661•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Changchun High & New Technology Industry Group publishes news
Free account required • Unsubscribe anytime